Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study

Background: Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxicity. TAF is available for older patients, with bone...

Full description

Bibliographic Details
Main Authors: Giacomo Stroffolini, Valentina Dodaro, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio, Lucio Boglione
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Journal of Clinical Virology Plus
Subjects:
HBV
Tenofovir disoproxil fumarate
Tenofovir alafenamide fumarate
Nephrotoxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S2667038023000418

Similar Items

Similar Items